The expression of USP22 is associated tightly with the sensitivity of HCC cells to various chemotherapeutics (i.e., sorafenib, doxorubicin and fluorouracil).[5, 8] Therefore, USP22‐specific gene therapy seems to be a promising method for reversing the cancer stemness and sensitizeing HCC cells to chemotherapeutics. Here, USP22 is linked to hepatocellular carcinoma.